Alice R. Correa e Castro Costa

Alice R. Correa e Castro Costa

Auto-generated profile, based on publicly available information

Alice R. Correa e Castro Costa

Department of Medicine and Nursing and Scientific Diving Unit, Universidade Federal de Viçosa, Viçosa, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Space: Science & Technology
Verified
Journal Article
Closed access
ACAlice R. C. e Castro-Costa
Alice R. C. e Castro-Costa
RSRodrigo Siqueira-Batista
Rodrigo Siqueira-Batista
FAFabíola A. Alcântara
Fabíola A. Alcântara
Thais RussomanoThais Russomano
Thais Russomano
MSMarlise A. Santos
Marlise A. Santos
OCOswaldo M. Del Cima
Oswaldo M. Del Cima
Introduction: Exposure of the human body to the aerospace environment is capable of producing various physiological changes, which contributes to greater susceptibility of acquiring viral and/or bacterial infections. Objective: To review studies on the use of antimicrobials in space to provide up-to-date information on the treatment of infectious diseases and contribute to the safety and well-being of astronauts on space voyages. Method: Integrative literature review, using DeCS (https://decs.bvsalud.org/) and PubMed ( https://pubmed.ncbi.nlm.nih.gov/ ). Results and Discussion: Prolonged exposure to microgravity, radiation, and confinement can potentially affect the dynamics of interactions between microorganisms and Homo sapiens , causing astronauts to be more susceptible to infections in the aerospace environment. This context becomes more complex when we consider the greater possibility of drug-resistant bacterial strains emerging—due to radiation-related mutations—and the conditions that affect antimicrobial stability, especially excessive vibrations, a carbon dioxide-rich atmosphere, and variations in humidity temperature fluctuations. Additionally, physiological changes experienced by humans in the extraterrestrial environment—e.g., cardiovascular, respiratory, and renal—can alter the pharmacokinetics of antimicrobials. Conclusion: Understanding the context in which astronauts are inserted, the risks involved, and how to avoid theses is essential for ensuring the safety and continuity of space missions with regards to diseases and the use of antimicrobials, which will allow humanity in space to have a “long and prosperous life”.

12 July 2024 in Brazilian Journal of Health and Biomedical Sciences
Verified
Journal Article
Open access
ACAlice R. Correa e Castro Costa
Alice R. Correa e Castro Costa
AGAndréia Patrícia Gomes
Andréia Patrícia Gomes
EVEduardo Vinícius Vieira Varejão
Eduardo Vinícius Vieira Varejão
RBRomario Brunes
Romario Brunes
WTWalter Tavares
Walter Tavares
RSRodrigo Siqueira-Batista
Rodrigo Siqueira-Batista
Introduction: Piperacillin-tazobactam, a broad-spectrum penicillin, is an important option in the treatment of infections, especially in critically ill patients who exhibit high rates of resistance to various antimicrobial agents. Understanding this medication and updates on its clinical use is of paramount significance to guide precise therapeutic choices aimed at the optimization of patient care. Objective: To describe the main pharmacological and therapeutic aspects of piperacillin-tazobactam, highlighting its clinical application and updates related to its use. Methods: A narrative review of the literature was conducted in order to provide an update on the most relevant aspects related to piperacillin-tazobactam, including (1) a brief history; (2) chemical structure; (3) mechanism of action; (4) resistance mechanisms; (5) spectrum; (6) major clinical uses; and (7) adverse effects. Results: The safe use of piperacillin-tazobactam requires rapid testing for antimicrobial resistance patterns, thus discouraging its empirical use in cases of ESBL-producing microorganisms. In patients undergoing renal replacement therapy, antibiotic goals must be established promptly. For critically ill patients, monitoring pharmacodynamic and pharmacokinetic variability is essential. Conclusion: Piperacillin-tazobactam remains a vital drug in the management of critically ill patients, while requiring constant updates. In addition, further studies are required, especially concerning its continuous use and the selection of alternatives to carbapenem-resistant medications.